The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC).
The lipid lowering drug Gemfibrozil significantly increased the levels of HDL-apoproteins, apoA-I and apoA-II in a group of 20 Swedish hyperlipemic males who were given 1200 mg daily of the drug for 8 weeks and thereafter submitted to a 4 weeks placebo period. It strikingly increased serum reserve cholesterol in binding capacity (SRCBC). No change was observed in "free" apoA-I or inthe level of Lp(a) lipoprotein. The results suggest that the effect of Gemfibrozil on HDL, may be particularly striking on a subclass (or on subclasses) of HDL responsible for most of SRCBC. The findings suggest that Gemfibrozil may become a useful drug for hyperlipidemic people, if its safety in pharmacological doses can be established.
D001053:Apolipoproteins / Q000097:blood*; D002784:Cholesterol / Q000097:blood*; D002986:Clinical Trials as Topic; D015248:Gemfibrozil; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000494:pharmacology*; D014631:Valerates / Q000494:pharmacology*; D014992:Xylenes / Q000494:pharmacology
D001053:Apolipoproteins; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D010421:Pentanoic Acids; D014631:Valerates; D014992:Xylenes; D002784:Cholesterol; D015248:Gemfibrozil